Gilead Sciences vs Moderna (GILD vs MRNA)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Gilead Sciences is the larger company by revenue ($29.4B vs $1.9B) and market value ($161.2B vs $26.6B). Gilead Sciences has grown revenue faster over the last 4 fiscal years (+7.8% cumulative vs -89.5%).
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that develops and markets medicines to treat life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. Its product portfolio includes oral antiretroviral therapies for HIV, treatments for liver diseases like hepatitis B and C, oncology therapies including CAR T-cell treatments, and antifungal and antiviral drugs. The company serves healthcare providers and patients worldwide through its commercial operations in over 35 countries.
About Moderna
Moderna, Inc. develops medicines based on messenger RNA (mRNA) technology to treat and prevent diseases. Its main products include COVID-19 vaccines Spikevax and mNEXSPIKE, and the respiratory syncytial virus vaccine mRESVIA. The company serves patients globally and is advancing a pipeline of vaccines and therapies for infectious diseases, oncology, and rare diseases.
Head to head (GILD FY2025 vs MRNA FY2025)
| Metric | GILDFY2025 | MRNAFY2025 |
|---|---|---|
| Revenue | $29.44B | $1.94B |
| Revenue growth (YoY) | 2.4% | -39.9% |
| Gross margin | 78.8% | — |
| Operating margin | 34.0% | — |
| Net margin | 28.9% | — |
| Net income | $8.51B | $-2.82B |
| Diluted EPS | $6.78 | $-7.26 |
| FCF margin | 32.1% | — |
| ROE | 37.6% | -32.6% |
| Debt / equity | 1.0× | 0.1× |
| Market cap | $161.19B | $26.59B |
| P/E (TTM) | 17.7× | — |
Fundamentals are from each company’s SEC filings (GILD FY2025, MRNA FY2025). P/E and market cap are derived from recent market prices and update daily.
Five-year trend (as reported)
| Revenue | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| GILD | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B |
| MRNA | $18.47B | $19.26B | $6.85B | $3.24B | $1.94B |
Peer standing
Where each company ranks among the 71 biotech companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | GILD | MRNA |
|---|---|---|
| Revenue growth (YoY) | +2.4%33rd percentile of 64 | -39.9%14th percentile of 64 |
| ROE | 37.6%92nd percentile of 61 | -32.6%47th percentile of 61 |
| Debt / equity | 0.98×78th percentile of 19 | 0.07×11th percentile of 19 |
| Short interest (days to cover) | 2.66d23rd percentile of 71 | 4.61d49th percentile of 71 |
Short interest
| FINRA settlement data | GILD | MRNA |
|---|---|---|
| Shares sold short | 25.5M | 53.2M |
| Change vs prior settlement | +6.8% | -9.3% |
| Days to cover | 2.66 | 4.61 |
| As of settlement | 2026-06-30 | 2026-06-30 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 open-market activity | GILD | MRNA |
|---|---|---|
| Buys | 0 | 0 |
| Sells | 18 ($10.8M) | 6 ($9.8M) |
Open-market purchases and sales reported on SEC Form 4 (grants, exercises and tax withholding excluded). For context, about 16% of covered companies saw any open-market insider buy in a 90-day window.
Held by the same investors
8 tracked 13F managers hold both Gilead Sciences and Moderna as of their latest quarterly filings: AQR Capital Management, Bridgewater Associates, Citadel Advisors, D. E. Shaw, Millennium Management, Point72 Asset Management, Renaissance Technologies, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
AMGN vs GILDBIIB vs GILDEXEL vs GILDGILD vs NBIXGILD vs RVMDGILD vs TECHAll biotech stocks →All comparisons →
Track GILD and MRNA
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.